JP6238910B2 - 免疫グロブリンを用いた粘膜炎の治療 - Google Patents

免疫グロブリンを用いた粘膜炎の治療 Download PDF

Info

Publication number
JP6238910B2
JP6238910B2 JP2014560392A JP2014560392A JP6238910B2 JP 6238910 B2 JP6238910 B2 JP 6238910B2 JP 2014560392 A JP2014560392 A JP 2014560392A JP 2014560392 A JP2014560392 A JP 2014560392A JP 6238910 B2 JP6238910 B2 JP 6238910B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
iga
mucositis
composition according
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014560392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513554A5 (enExample
JP2015513554A (ja
Inventor
クリストフ・アエビ
クリスティーナ・ルアー ゾニア
クリスティーナ・ルアー ゾニア
アレクサンダー・シャウブ
シルヴィア・ミーシャー
アードリアン・チュルヒャー
ピエール・ボナーブルグ セドリック
ピエール・ボナーブルグ セドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
ZLB Bioplasma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZLB Bioplasma AG filed Critical ZLB Bioplasma AG
Publication of JP2015513554A publication Critical patent/JP2015513554A/ja
Publication of JP2015513554A5 publication Critical patent/JP2015513554A5/ja
Application granted granted Critical
Publication of JP6238910B2 publication Critical patent/JP6238910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2014560392A 2012-03-09 2013-03-08 免疫グロブリンを用いた粘膜炎の治療 Active JP6238910B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12158939.4 2012-03-09
EP12158939.4A EP2636683A1 (en) 2012-03-09 2012-03-09 Treatment of mucositis with Immunoglobulin
PCT/EP2013/054722 WO2013132063A1 (en) 2012-03-09 2013-03-08 Treatment of mucositis with immunoglobulin

Publications (3)

Publication Number Publication Date
JP2015513554A JP2015513554A (ja) 2015-05-14
JP2015513554A5 JP2015513554A5 (enExample) 2016-03-17
JP6238910B2 true JP6238910B2 (ja) 2017-11-29

Family

ID=45808320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560392A Active JP6238910B2 (ja) 2012-03-09 2013-03-08 免疫グロブリンを用いた粘膜炎の治療

Country Status (10)

Country Link
US (1) US9546209B2 (enExample)
EP (2) EP2636683A1 (enExample)
JP (1) JP6238910B2 (enExample)
KR (1) KR102120620B1 (enExample)
CN (1) CN104254543B (enExample)
AU (1) AU2013201394B2 (enExample)
CA (1) CA2865810C (enExample)
DK (1) DK2822966T3 (enExample)
ES (1) ES2660157T3 (enExample)
WO (1) WO2013132063A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102142261B1 (ko) 2012-03-09 2020-08-11 체에스엘 베링 아게 분비형 면역글로불린을 포함하는 조성물
EP2636684A1 (en) * 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
CA3043012A1 (en) 2016-11-10 2018-05-17 Becton, Dickinson And Company Timeline system for monitoring a culture media protocol
EP4662233A1 (en) * 2023-01-13 2025-12-17 Michael R. Simon Process for preparation of secretory iga and secretory igm and use thereof for treating necrotizing enterocolitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057993A1 (en) * 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
EP1068871A1 (en) * 1999-07-07 2001-01-17 Jean-Paul Perraudin Novel methods and medicament for treating infections diseases involving microbial biofilms
EP2725035A1 (en) * 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract

Also Published As

Publication number Publication date
HK1204629A1 (en) 2015-11-27
DK2822966T3 (en) 2018-02-26
AU2013201394A1 (en) 2013-09-26
WO2013132063A1 (en) 2013-09-12
CA2865810C (en) 2022-09-06
CN104254543B (zh) 2018-06-05
EP2822966A1 (en) 2015-01-14
AU2013201394B2 (en) 2015-09-03
JP2015513554A (ja) 2015-05-14
ES2660157T3 (es) 2018-03-21
KR20140145587A (ko) 2014-12-23
US9546209B2 (en) 2017-01-17
CA2865810A1 (en) 2013-09-12
KR102120620B1 (ko) 2020-06-10
US20150030613A1 (en) 2015-01-29
CN104254543A (zh) 2014-12-31
EP2822966B1 (en) 2017-11-29
EP2636683A1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
EP3157565B1 (en) Treatment of polybacterials infections
JP6238910B2 (ja) 免疫グロブリンを用いた粘膜炎の治療
CN104968797A (zh) 金黄色葡萄球菌表面决定簇的抗体
JP2019038834A (ja) 分泌様免疫グロブリンを含む組成物
AU2012236106B2 (en) Treatment for dermatological pathologies
TW202228776A (zh) 抗tslp抗體藥物組合物及其用途
US20220380484A1 (en) Antibodies for binding plasminogen
HK1204629B (en) Treatment of mucositis with immunoglobulin a
KR102241619B1 (ko) 병원체의 면역 억제 기능을 저해하는 모노클로날 항체, 그의 항원 결합 단편 및 이러한 항체를 생성하는 하이브리도마
CN107459575B (zh) 具有抑制病原体的免疫抑制功能的单克隆抗体，其抗原结合片段，以及产生该抗体的杂交瘤
KR101453516B1 (ko) 항-ｖｅｇｆ 항체를 포함하는 자가면역질환 예방 및 치료용 조성물
TWI665215B (zh) 具有抑制致病原的免疫抑制功能的單株抗體，其抗原結合片段，以及產生該等抗體的融合瘤
HK1236126A1 (en) Treatment of polybacterials infections
HK1236126B (en) Treatment of polybacterials infections
JPWO2020018584A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170628

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171031

R150 Certificate of patent or registration of utility model

Ref document number: 6238910

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250